PostEra

Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra, covering up to five small-molecule programs. As part of the agreement, Amgen will also secure a future option to leverage PostEra’s AI technology for its own pipeline development. Financial Details and PostEra’s Track RecordWhile the…